Binding of desloratadine and atenolol with bovine serum albumin and their in-vitro interactions

Authors

  • Khondoker Shihab-us-Sakib Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, (Bangladesh)
  • Mohammad A. Islam Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, (Bangladesh)
  • M. Moniruzzaman Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, (Bangladesh)
  • Anwar Hussein Department of Pharmacy, The University of Asia Pacific, Dhaka-1209, (Bangladesh)
  • M. Mahboob Hossain Department of Mathematics and Natural Sciences, Microbiology Programme, BRAC University, Mohakhali, Dhaka-1212, (Bangladesh)
  • Mohammad A. Mazid Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, (Bangladesh)

Keywords:

Atenolol, desloratadine, drug-drug interaction, bovine serum albumin, equilibrium dialysis

Abstract

Aims: The binding of atenolol a selective β1 receptor antagonist and desloratadine, an H1 receptor antagonist, to bovine serum albumin.

Methods: The analysis of binding was studied by equilibrium dialysis method (ED) using ranitidine and diazepam as site-1 and site-2 specific probe, respectively.

Results: The study suggested two sets of association constants, for atenolol: high affinity association constant (k1 = 5 x 10-5 M-1) with low capacity (n1 = 2) and low affinity association constant (k2 = 2.5 x 10-5 M-1) with high capacity (n2 = 5), while for desloratadine: high affinity association constant (k1 = 45 x 10-5 M-1) with low capacity (n1 = 1.3) and low affinity association constant (k2 = 5 x 10-5 M-1) with high capacity (n2 = 2.5) at pH 7.4 and 27 °C. During concurrent administration of atenolol and desloratadine in presence or absence of ranitidine or diazepam, desloratadine causes the release of atenolol from its binding site on BSA resulting reduced binding of atenolol to BSA. The increment in free fraction of atenolol was from 84.01% to 99 % upon the addition of increased concentration of only desloratadine at a concentration of 0 x 10-5 M to 14 x 10-5 M. In presence of diazepam as site-II specific probes, desloratadine further increases the free fraction of atenolol was from 0.45% to 14.3%.

Conclusion: These data were indicative for the interaction of higher concentration of desloratadine at the binding sites on BSA changing the pharmacokinetics properties of atenolol.

Downloads

Download data is not yet available.

References

Agon P, Goethals P, VanHaver D, Kaufman JM. Permeability of the blood-brain barrier for atenolol studied by positron emission tomography. J Pharm Pharmacol. 1991; 43 (8):597-600.

Amery A, DePlaen J, Lijnen P, McAinsh J, Reybrouk, T. Relationship between blood level of atenolol & pharmacologic effect. Clin Pharmac Ther. 1997; 21: 691-9.

Brown HC, Carruthers SG, Johnston GD et al. Clinical pharmacologic observations on atenolol a P-adrenoceptor blocker. Clin Pharmac Ther. 1976; 20:524-34.

Mann R, Pearce G, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000; 320 (7243):1184-6.

Bachert C, Van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther. 2007; 29(9): 1795-802.

Demoly P, Dreyfus I, Dhivert-Donnadieu H, Mesbah K. Desloratadine for the treatment of cypress pollen-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2009; 103(3):260-6.

Conway FJ, Fitzgerald JD, McAinsh J, Rowlands DJ, Simpson WT. Human pharmacokinetic and pharmacodynamic studies on atenolol (ICI 66082), a new cardioselective P-adrenoceptor blocking drug. Br J clin Pharmac. 1976; 3:267-72.

Wan SH, Koda RT, Maronde RF. Pharmacokinetic, pharmacology of atenolol and effect of renal disease. Br J clin Pharmac. 1979; 7:569-74.

Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978; 13(2):81-89.

Kirch W, Görg KG. Clinical pharmacokinetics of atenolol--a review. Eur J Drug Metab Pharmacokinet. 1982; 7(2):81-91.

Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol. 2006; 98(6):555-8.

Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol. 2005; 5-6:337-40.

Alam MA, Awal MA, Mostofa M, Islam MK, Subhan N. In-vitro displacement interaction of atenolol and amlodipine on binding with bovine serum albumin when co-administered. Bangladesh J Pharmacol. 2007; 2:20-6.

Czendlik CH, Sioufi A, Preiswerk G, Howald H. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol. 1997; 52(6):451-9.

Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol. 2004; 44(11):1252-9.

Gupta S, Banfield C, Kantesaria B et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 2001; 23(3):451-66.

Affrime M, Gupta S, Banfield C, Cohen AA. Pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet. 2002; 41 (Suppl 1):13-9.

Scharf M, Berkowitz D. Effects of desloratadine and alcohol coadministration on psychomotor performance. Curr Med Res Opin. 2007; 23(2):313-21.

Ferdosi KA, Nazim UK, Nazmus Sadat AFM, Hossain MM, Mazid MA. Interaction of palmitic acid with losartan potassium at the binding sites of bovine serum albumin. Ars Pharm. 2010; 51(1):28-36.

Jiunn HL, David MC, Daniel ED. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinetics. 1987; 12:402-32.

Rahman MH, Yamasaki K, Shin YH, Lin CC, Otagirin M. Characterization of high affinity binding sites of non-steroidal anti-inflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull. 1993; 16(11):1169-74.

Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev March. 1981; 33:17-53.

He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992; 358:209-15.

Downloads

Published

2012-12-20

How to Cite

1.
Shihab-us-Sakib K, Islam MA, Moniruzzaman M, Hussein A, Mahboob Hossain M, Mazid MA. Binding of desloratadine and atenolol with bovine serum albumin and their in-vitro interactions. Ars Pharm [Internet]. 2012 Dec. 20 [cited 2024 Aug. 24];53(4):21-7. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4689

Issue

Vol. 53 No. 4 (2012)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).